|
|
Diagnosis and Rational Therapeutic Selection in the Management of Invasive Mycoses |
|
1) Clinical Perspectives: Optimal Use of PK/PD in Antifungal Selection
2) Diagnosis and Management of Endemic and Opportunistic Mycoses
|
Program Overview
|
- Dr. Richard Drew and Dr. James Lewis discuss the importance of using pharmacokinetic and pharmacodynamic parameters when choosing an appropriate antifungal agent. Clinically relevant PK/PD differences among the antifungal classes are also reviewed.
- Dr. George Sarosi and Dr. Thomas Patterson review the challenges clinicians face in the diagnosis and treatment of endemic and opportunistic fungal infections. The discussion is based on an article authored by Dr. Sarosi titled, “Fungal Infection and Their Treatment in the Intensive Care Unit” that was published in Current Opinion in Critical Care.
|
Target Audience |
This activity has been designed to meet the needs of pharmacists and all other healthcare professionals who care for and who may be involved in the diagnosis, management, and treatment of invasive fungal infections.
|
Learning Objectives |
At the conclusion of this activity, participants should be better able to:- Discuss the role of pharmacokinetic/pharmacodynamic characteristics in the selection of antifungal agents for the treatment of invasive fungal infections
- Describe recent developments in the diagnosis and treatment of invasive fungal infections in the Intensive Care Unit
|
Faculty |
|
Richard H. Drew, PharmD
Professor of Pharmacy
Campbell University School of Pharmacy
Duke University Medical Center
Durham, North Carolina
James S. Lewis, PharmD
Infectious Diseases Pharmacy Programs Manager
Clinical Assistant Professor
University Health System, Department of Pharmacy
University of Texas Health Science Center, San Antonio
San Antonio, Texas
George A. Sarosi, MD
Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana
Thomas F. Patterson, MD
Professor of Medicine
The University of Texas Health Science Center
San Antonio, Texas
|
Pharmacist Accreditation |
 The American Academy of CME (Academy) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Academy has assigned 1 contact hour (0.1 CEU) of continuing pharmacy education credit to this activity. ACPE Universal Program Number: 297-999-07-020-HO1-P.
|
| Release Date: Friday, September 28, 2007 |
| Expiration Date: Wednesday, October 1, 2008 |
Estimated Time to Complete Activity: 1 hour
|
Disclosure Statement |
According to the disclosure policy of the Academy, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the Academy to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
|
Disclosures |
Richard H. Drew, PharmD has received research support from Cubist, NeuTec, and Schering-Plough. He serves as a consultant for Merck, Schering-Plough, and Theravance. Also, he is a speaker for Enzon, Ortho-McNeil, Sanofi-Aventis, and Schering-Plough Corporation.
James S. Lewis, PharmD serves as a consultant and and is a speaker for Astellas, Pfizer, and Schering-Plough.
George A. Sarosi, MD is a member of the Speakers Bureau for Merck and Pfizer.
Thomas F. Patterson, MD has received research support from Astellas Pharma US Inc., Enzon, Merck & Co, Nektar Therapeutics, Pfizer, and Schering-Plough Corporation; Dr. Patterson was the principal investigator and the funds were paid to his institution. Additionally, he serves as a consultant to Astellas Pharma US Inc., Basilea, Merck & Co, Pfizer, Schering-Plough Corporation, and Stiefel Laboratories and is a member of the Speakers Bureau for Astellas Pharma US Inc., Merck & Co, Pfizer, and Schering-Plough Corporation.
Planning Committee Members: Karen Wetzel, American Academy of CME and Vesna Drenovac, RPh, MS, and Marco Cicero, PhD, Vemco MedEd have disclosed that they have no relevant financial relationships with any commercial interests.
|
Off-label Disclosure Statement |
At the time of the release of this CE activity, the following non-FDA-approved off-label use of the following antifungal agent is discussed in “Clinical Perspectives: Optimal Use of PK/PD in Antifungal Selection”: liposomal formulation of amphotericin B at a dose of 10 mg/kg per day.
|
Fee |
There is no fee to participate in this educational activity.
|
Method of Participation |
|
Please note that you must listen to both programs to receive credit. To receive credit for your participation in this CE podcast activity, please complete the following steps:
- Review the CE information for both programs including the target audience, learning objectives, and disclosures.
- Listen to and review both programs carefully.
- Complete the CE Post-test, selecting the most appropriate response to each question.
- Complete the CE Evaluation Form and Credit Information.
- Fax the Evaluation Form and Credit Information to (609) 921-6428 or mail to: American Academy of CME, 186 Tamarack Circle, Skillman, NJ 08558. Documentation of credit will be mailed within 6-8 weeks following receipt of your materials.
|
|
Hardware/Software Requirements
|
| All educational activities are accessible via Internet Explorer and Netscape browsers. A high speed
connection is highly recommended. Windows Media Player, sound card, and speakers are required for
audio. You must have Adobe Acrobat Reader version 4 or above installed on your computer to view PDF
files. If you do not have Acrobat Reader, you can download it for free at Adobe.com |
|
|
Jointly sponsored by the American Academy of CME, Inc. and Vemco MedEd, LLC
Supported by an educational grant from Schering-Plough Corporation
|
|
podcasts
